S&P・Nasdaq 本質的価値 お問い合わせ

Roivant Sciences Ltd. ROIV NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • GB • USD

SharesGrow Score
64/100
4/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$31.50
+7.2%

Roivant Sciences Ltd. (ROIV) has 20 既知のインサイダーおよび機関投資家保有者の記録. 最大保有者は Dexcel Pharma Technologies Ltd. 102,849,443 株保有. その他の主要保有者には Oren Dan および SVF Investments (UK) Ltd.

過去12ヶ月間にインサイダーは 67 件の取引を実施 ROIV 株式 — 3 件の買い (評価額 $5.75M) および 34 件の売り (評価額 $204.8M). インサイダーの売りが買いを上回っています.

ROIV インサイダー保有状況

最大保有者
Dexcel Pharma Technologies Ltd.
102,849,443 株
買い(12ヶ月)
3
$5.75M 評価額
売り(12ヶ月)
34
$204.8M 評価額
12ヶ月取引活動
買い 4%
売り 51%
インサイダー上位保有者
# 氏名 役職 保有株数 最終申告日 相対規模
1 Dexcel Pharma Technologies Ltd. Director 102,849,443 2022-11-14
100%
2 Oren Dan Director 98,840,843 2022-04-26
96%
3 Svf Investments (uk) Ltd 10 Percent Owner 73,031,667 2023-10-02
71%
4 Sumitomo Chemical Co., Ltd. 10 Percent Owner 71,251,083 2023-06-26
69%
5 Ramaswamy Vivek 10 Percent Owner 37,861,115 2025-06-23
37%
6 Sukhatme Mayukh President & CIO 18,677,617 2026-04-01
18%
7 Gline Matthew CEO 17,025,890 2026-04-01
17%
8 Gold Daniel Allen Director 15,928,113 2026-02-13
15%
9 Manchester Keith S Director 15,928,113 2026-02-13
15%
10 Qvt Financial Lp Other: Director By Deputization 15,928,113 2026-02-13
15%
11 Torti Frank President and Vant Chair 13,576,512 2026-04-02
13%
12 Venker Eric President & Immunovant CEO 1,647,546 2026-03-19
2%
13 Viking Global Investors Lp 10 Percent Owner 641,010 2023-06-26
1%
14 Viking Global Performance Llc 10 Percent Owner 641,010 2023-06-26
1%
15 Pulik Richard CFO 236,867 2026-03-24
0%
16 Kumar Rakhi Chief Accounting Officer 162,306 2025-02-24
0%
17 Oren Ilan Director 119,428 2026-01-22
0%
18 Momtazee James C Director 109,030 2026-01-22
0%
19 Humes Jennifer Chief Accounting Officer 97,729 2026-03-24
0%
20 Lo Andrew Director 52,142 2022-09-19
0%
最近の取引 (過去12ヶ月)
日付 氏名 役職 種類 株数 株価 価値
2026-03-31 Torti Frank President and Vant Chair RSU 源泉徴収 160,035 $27.70 $4.43M
2026-03-31 Gline Matthew CEO RSU 源泉徴収 304,684 $27.70 $8.44M
2026-03-30 Gline Matthew CEO オプション行使(売却) 2,178,150 - -
2026-03-31 Sukhatme Mayukh President & CIO RSU 源泉徴収 187,512 $27.70 $5.19M
2026-03-30 Sukhatme Mayukh President & CIO オプション行使(売却) 1,306,889 - -
2026-03-26 Fitzgerald Meghan Director 情報に基づく売り 70,000 $27.45 $1.92M
2026-03-20 Humes Jennifer Chief Accounting Officer RSU 源泉徴収 14,526 $27.70 $402.37K
2026-03-20 Pulik Richard CFO RSU 源泉徴収 1,546 $27.70 $42.82K
2026-03-17 Venker Eric President & Immunovant CEO 情報に基づく売り 200,000 $28.24 $5.65M
2026-03-16 Epperly Melissa B, Director 情報に基づく売り 41,861 $28.68 $1.2M
2026-02-20 Pulik Richard CFO RSU 源泉徴収 1,000 $27.15 $27.15K
2026-02-20 Venker Eric President & Immunovant CEO RSU 源泉徴収 7,051 $27.15 $191.43K
2026-02-23 Torti Frank President and Vant Chair オプション行使(売却) 587,390 $3.85 $2.26M
2026-02-20 Torti Frank President and Vant Chair オプション行使(売却) 1,012,610 $3.85 $3.9M
2026-02-19 Torti Frank President and Vant Chair オプション行使(売却) 1,400,000 $3.85 $5.39M
2026-02-13 Venker Eric President & Immunovant CEO 情報に基づく売り 200,000 $26.49 $5.3M
2026-02-13 Gold Daniel Allen Director 情報に基づく売り 225,000 $26.50 $5.96M
2026-02-12 Gold Daniel Allen Director 情報に基づく売り 275,000 $26.76 $7.36M
2026-02-11 Gold Daniel Allen Director 情報に基づく売り 425,000 $26.67 $11.33M
2026-02-13 Qvt Financial Lp Other: Director By Deputization 情報に基づく売り 225,000 $26.50 $5.96M
2026-02-12 Qvt Financial Lp Other: Director By Deputization 情報に基づく売り 275,000 $26.76 $7.36M
2026-02-11 Qvt Financial Lp Other: Director By Deputization 情報に基づく売り 425,000 $26.67 $11.33M
2026-02-13 Manchester Keith S Director 情報に基づく売り 225,000 $26.50 $5.96M
2026-02-12 Manchester Keith S Director 情報に基づく売り 275,000 $26.76 $7.36M
2026-02-11 Manchester Keith S Director 情報に基づく売り 425,000 $26.67 $11.33M
お問い合わせ
🎓
SharesGrow アカデミー
本質的価値の計算と割安株の見つけ方を学ぶ。
毎週のライブセッション
メッセージを送る